A Phase 1 Study of the Safety and Tolerability of BMS 986148 in Subjects With Advanced and/or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs BMS 986148 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 12 Dec 2017 Status changed to discontinued.
- 30 Jun 2017 Planned primary completion date changed from 27 Jul 2017 to 19 Oct 2017.
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.